National Harm Reduction Technical Assistance and Syringe Services Program (SSP) Monitoring and Evaluation Funding Opportunity
The purpose of this program is to strengthen harm reduction programs in order to prevent infectious disease resulting from injection drug use, and improving health outcomes for people who inject drugs; including strengthening linkage to medication-assisted treatment. It is comprised of three components: technical assistance, communications and monitoring and evaluation.
General information about this opportunity
Last Known Status
Active
Program Number
93.488
Federal Agency/Office
Centers For Disease Control and Prevention, Department of Health and Human Services
Type(s) of Assistance Offered
B - Project Grants
Program Accomplishments
Not applicable.
Authorization
Section Sections 301 and 317 (k)(2) of the Public Health Service Act (42 U.S.C. section 241 and 274b), as amended.
Who is eligible to apply/benefit from this assistance?
Applicant Eligibility
Not applicable.
Beneficiary Eligibility
Not applicable.
Credentials/Documentation
Not applicable.
What is the process for applying and being award this assistance?
Pre-Application Procedure
Preapplication coordination is not applicable.
Application Procedure
This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.
Award Procedure
Not applicable
Deadlines
Contact the headquarters or regional location, as appropriate for application deadlines
Approval/Disapproval Decision Time
Not applicable.
Appeals
From 120 to 180 days. Not applicable
Renewals
More than 180 days.
How are proposals selected?
Not applicable.
How may assistance be used?
The purpose of this program is to increase the capacity of government and non-government organizations to strengthen harm reduction programs, including Syringe Services Programs (SSPs). Activities by the cooperative agreement program include technical assistance, communication, and monitoring and evaluation of harm reduction programs. These activities will facilitate and sustain efforts to effectively and efficiently address the infectious disease consequences of opioid use and injection drug use.
What are the requirements after being awarded this opportunity?
Reporting
Performance Reports: Performance reports are required as part of the progress report
Auditing
Not applicable.
Records
Financial records, supporting documentation, statistical records, and all other reports pertinent to the program shall be retained for a minimum of 3 years, or until completion and resolution of any pending audits or resolutions. In all cases records must be retained until resolution of any audit findings. Property records must be retained in accordance with 45 CFR 92.42.
Other Assistance Considerations
Formula and Matching Requirements
Statutory formula is not applicable to this assistance listing.
Matching requirements are not applicable to this assistance listing.
MOE requirements are not applicable to this assistance listing.
Length and Time Phasing of Assistance
September 1, 2019 Not applicable
Who do I contact about this opportunity?
Regional or Local Office
None/Not specified.
Headquarters Office
Lisa Williams
1600 Clifton Road, MS E-07
Atlanta, GA 30333 USA
LRW3@cdc.gov
Phone: 4046391877
Financial Information
Account Identification
75-0953-0-1-550
Obligations
(Cooperative Agreements (Discretionary Grants)) FY 18 FY 19 FY 20 - (Cooperative Agreements) FY 18$0.00; FY 19 est $4,000,975.00; FY 20 est $975,000.00; -
Range and Average of Financial Assistance
Not applicable
Regulations, Guidelines and Literature
Not applicable.
Examples of Funded Projects
Not applicable.